You can feel the problem before you see it. A patient sits in a wheelchair, or lies in a bed, and the pressure never moves. The skin, starved of blood flow, begins to break down. It’s a quiet, expensive, and deeply human crisis that costs the U.S. healthcare system billions each year and defines the daily dread for nurses and caregivers. Jessica Bussert, RN, has spent her career watching it happen. Now, through her company Wave Therapeutics, she’s trying to build a cushion that watches back.
Founded in 2017 and based in Nashville, Indiana, Wave is developing what it calls smart therapeutic cushioning. The flagship product is a seat cushion embedded with a microprocessor-controlled pump that automates two medically recognized therapies: dynamic pressure relief and sequential compression. The idea is simple in ambition, complex in execution. Instead of relying on a caregiver to manually reposition a patient every two hours,a standard of care that is often logistically impossible,the cushion does it for them, shifting pressure points and gently massaging tissue to promote circulation. It’s a piece of soft robotics aimed at a stubbornly analog corner of medicine.
The Nurse’s Algorithm
Bussert is the company’s founder and CEO, and her background is the product’s origin story. An emergency room nurse and self-described lifelong technologist, she brings a practitioner’s intimacy with the problem to the engineering challenge. The company’s public narrative is built around this duality: the clinical eye and the technical hand. Wave’s cushion isn’t just a piece of foam with a motor; it’s designed to integrate with the workflow and liability concerns of long-term care facilities and hospitals. The value proposition is framed in the language of those facilities: reduced treatment costs, shorter hospital stays, and lower legal liabilities from preventable injuries [Perplexity Sonar Pro Brief, 2024].
The product roadmap suggests a vision beyond passive hardware. Current prototypes are paired with an analytics platform for remote patient monitoring, allowing staff or family to track compliance and pressure buildup [techpoint.org, 2026]. A planned second generation would incorporate an array of sensors to detect early warning signs like changes in skin temperature [techpoint.org, 2026]. This moves the device from a preventative aid to a diagnostic tool, a shift that could change its reimbursement profile and clinical utility.
Traction Through Partnerships
For a hardware medtech startup, the path to market is paved with prototypes and partnerships. Wave’s disclosed traction reflects this grind. The company has raised approximately $1.6 million in total funding, according to PitchBook, from a consortium of specialized investors including mHUB Ventures, the WBL Fellows Program, and Nurse Capital,a fund whose name underscores the founder’s background [PitchBook, 2024]. It has progressed through accelerators like Techstars and mHUB, milestones typical for a company refining its design for manufacture.
Perhaps the most significant validation comes from its collaboration with the Veterans Health Administration (VHA) Innovation Ecosystem and the Louis Stokes Cleveland VA Medical Center on the design of its initial wheelchair seat cushion [rehabpub.com, 2026]. Landing a development partner within the vast, byzantine VA system is a non-trivial signal. It suggests the technology addresses a recognized need within a massive, cost-conscious buyer that serves a high-risk population. The company states it has partner factories lined up and is working on factory-ready prototypes [ciconiamedical.com, 2026].
| Milestone | Detail | Source |
|---|---|---|
| Total Raised | ~$1.61M (estimated) | [PitchBook, 2024] |
| Key Investors | mHUB Ventures, WBL Fellows Program, Nurse Capital | [PitchBook, 2024] |
| Accelerators | Techstars, gBETA, mHUB Accelerator | [Pplexity Sonar Pro Brief, 2024] |
| Development Partner | Veterans Health Administration (VHA) Innovation Ecosystem | [rehabpub.com, 2026] |
| Team Size | 1-10 employees (estimated) | [LinkedIn, 2024] |
The Scale of the Sore
The market Wave is addressing is both enormous and agonizingly specific. Pressure injuries, commonly known as bedsores, are a brutal metric of systemic failure. They affect an estimated 2.5 million people annually in the U.S., and treating a single severe injury can add between $20,000 and $151,000 to a patient’s cost of care [nethealth.com, 2026]. The total annual cost to the healthcare system is pegged between $9.1 billion and $26.8 billion [nethealth.com, 2026]; [pmc.ncbi.nlm.nih.gov, 2026]. For facilities, these are not just clinical outcomes but financial and regulatory ones. Hospitals now face penalties for hospital-acquired pressure injuries, turning prevention from a moral imperative into a bottom-line necessity.
Wave’s initial focus is on the highest-risk, highest-cost settings: long-term care facilities, hospitals, and home health for mobility-impaired patients. But the company’s vision, as noted in its materials, stretches further. It has mentioned future applications for long-haul drivers and office workers [Perplexity Sonar Pro Brief, 2024]. This hints at a larger ambition,to move from a medical device to a consumer wellness product, from treating pathology to promoting general health. It’s a common startup arc, but one that requires navigating two completely different regulatory and sales landscapes.
The Hardware Hurdle
The bet is compelling, but the path is littered with the carcasses of well-intentioned medical hardware startups. The risks for Wave are not subtle, and they are primarily executional.
- The Manufacturing Cliff. Moving from a working prototype to a reliable, cost-effective, mass-produced medical device is a notorious valley of death. The company says it is finalizing design for manufacture and has factory partners lined up, but until units are shipping at scale, this remains the central, unproven gamble.
- The Reimbursement Maze. Even a perfect product needs a code. Securing insurance reimbursement for a new durable medical equipment (DME) category is a multi-year odyssey requiring clinical studies and regulatory navigation. Wave’s collaboration with the VA is a strong start, but it’s only a start.
- The Incumbent’s Chair. The market for pressure-relief surfaces is dominated by large, established players like Mölnlycke. These companies have deep sales relationships with hospital procurement departments and extensive product lines. Wave’s wedge is intelligence and automation, but it must convince budget-holders that its smarter cushion is worth displacing a known, cheaper alternative.
- Conflicting Signals. Public data on the company’s status is murky. While PitchBook reports $1.61 million raised, other sources like CB Insights cite a figure as low as $450,000 [CB Insights, 2024]. The company’s own LinkedIn page lists employee counts ranging from 1-10 to 11 [LinkedIn, 2024]. This noise is typical for an early-stage startup operating quietly, but it underscores the distance between potential and proven scale.
The company’s answer to these challenges appears to be focus. By partnering with the VA and targeting the acute needs of long-term care, it seeks a beachhead in a segment where the cost of failure (both human and financial) is so high that a premium on prevention is easier to justify.
The Next Twelve Months
For Wave Therapeutics, the immediate future is measured in physical milestones. The next year will be about transitioning from prototype to product. Key things to watch will be the announcement of a finalized manufacturing partner, the completion of any necessary regulatory clearances (like a 510(k) for its device class), and, crucially, the first named commercial deployment outside of a development partnership. A pilot with a major hospital system or senior living chain would be a powerful traction signal.
Financing will also be a focus. The ~$1.6 million in seed funding is sufficient for R&D and early prototyping but likely insufficient for inventory build-out and a commercial sales push. A Series A round, potentially led by a specialist medtech or healthcare investor, would be the logical next step to fund that transition from development to delivery.
Ultimately, the question Wave Therapeutics is built to answer isn’t merely technological. It’s cultural: in a care system stretched thin, where human attention is the scarcest resource, what happens when we offload the act of vigilance to a machine? The cushion’s gentle, automatic shift is a tiny, silent argument that the best care might not always look like care at all, but like something that simply, reliably, never forgets to move.
Sources
- [PitchBook, 2024] Wave Therapeutics funding and investor profile | https://pitchbook.com/profiles/company/266971-24
- [LinkedIn, 2024] Wave Therapeutics company page | https://www.linkedin.com/company/wavetherapeuticsinc
- [CB Insights, 2024] Wave Therapeutics company profile | https://www.cbinsights.com/company/wave-therapeutics
- [techpoint.org, 2026] Wave Therapeutics feature on sensor integration | https://techpoint.org
- [rehabpub.com, 2026] Article on Wave Therapeutics VA partnership | https://rehabpub.com
- [ciconiamedical.com, 2026] mHUB accelerator graduation feature | https://www.ciconiamedical.com/news/meet-the-10-medtech-startups-graduating-from-the-2023-mhub-accelerator
- [nethealth.com, 2026] Pressure injury market and cost data | https://nethealth.com
- [pmc.ncbi.nlm.nih.gov, 2026] Research on hospital-acquired pressure injury costs | https://pmc.ncbi.nlm.nih.gov